CD274 and small cell lung carcinoma: However, the combined use of chemotherapy and ICIs targeting programmed cell death ligand 1 (PD-L1), such as durvalumab and atezolizumab, has yielded only modest improvement in survival outcomes for SCLC patients (9, 47).